Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation

Kidney International

Volumn 62, Issue 3, 2002, Pages 1060-1067

  Cattaneo, Dario ^a   Perico, Norberto ^a   Gaspari, Flavio ^a   Gotti, Eliana ^a   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

CsA pharmacokinetics; Immunosuppression; Kidney transplantation; MPA pharmacokinetics; Steroid withdrawal

Indexed keywords

7 HYDROXYGLUCURONIDE; CYCLOSPORIN A; DRUG METABOLITE; GLUCOCORTICOID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG EXPOSURE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; TIME;

EID: 0036424769     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00531.x     Document Type: Article

References (31)

1. Sollinger HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60:225-232, 1995
2. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345:1321-1325, 1995
3. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61:1029-1037, 1996
4. Hale MD, Nicholls AJ, Bullingham RES, et al: The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 64:672-683, 1998
5. Bullingham RE, Nicholls A, Hale M: Pharmacokinetics of mycophenolate mofetil (RS61443): A short review. Transplant Proc 28:925-929, 1996
6. Van Gelder T, Hilbrands LB, Vanrenterghem Y, et al: A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68:261-266, 1999
7. Yamani MH, Starling RC, Goormastic M, et al: The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation 69:2326-2330, 2000
8. Meiser BM, Pfeiffer M, Schmidt D, et al: The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels. Transplant Proc 31:84-87, 1999
9. Fulton B, Markham A: Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51:278-298, 1996
10. Bullingham RES, Nicholls AJ, Kamm BR: Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429-455, 1998
11. Shipkova M, Armstrong VW, Wieland E, et al: Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 126:1075-1082, 1999
12. Smak Gregoor PJH, Van Gelder T, Hesse CJ, et al: Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: A cross-sectional study. Nephrol Dial Transplant 14:706-708, 1999
13. Smak Gregoor PJ, Hesse CJ, Van Gelder T, et al: Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients. Transplant Proc 30:1192-1193, 1998
14. Mourad M, Malaise J, Chaib Eddour D, et al: Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 47:88-94, 2001
15. Schuetz EG, Hazelton GA, Hall J, et al: Induction of digitoxigenin monodigitoxoside UDP-glucuronosyltransferase activity by glucocorticoids and other inducers of cytochrome P-450 in primary monolayer cultures of adult rat hepatocytes and in human liver. J Biol Chem 261:8270-8275, 1986
16. Li YQ, Prentice DA, Howard ML, et al: The effect of hormones on the expression of five isoforms of UDP-glucuronosyltransferase in primary cultures of rat hepatocytes. Pharm Res 16:191-197, 1999
17. Wishart GJ, Dutron GJ: Regulation of onset of development of UDP-glucuronosyltransferase activity towards o-aminophenol by glucocorticoids in late-foetal rat liver in utero. Biochem J 168:507-511, 1977
18. Gaspari F, Anedda MF, Signorini O, et al: Prediction of cyclosporine area under the curve using a three point sampling strategy after neoral administration. J Am Soc Nephrol 8:647-652, 1997
19. Tsina I, Chu F, Hama K, et al: Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma. J Chromatogr B 675:119-129, 1996
20. Cattaneo D, Gaspari F, Ferrari S, et al: Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 15:402-409, 2001
21. Sugioka N, Odani H, Kishimoto H, et al: Determination of a new immunosuppressant, mycophenolate mofetil, and its active metabolite, mycophenolic acid, in rat and human body fluids by high-performance liquid chromatography. J Chromatogr B 654:249-256, 1994
22. Nowak I, Shaw LM: Mycophenolic acid binding to human serum albumin: Characterization and relation to pharmacodynamics. Clin Chem 41:1011-1018, 1995
23. Perico N, Ruggenenti P, Gaspari F, et al: Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 54:56-60, 1992
24. Van Gelder T, Klupp J, Barten MJ, et al: Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23:119-128, 2001
25. Svensson CK, Woodruff MN, Baxter JG, Lalka D: Free drug concentration monitoring in clinical practice. Rationale and current status. Clin Pharmacokinet 11:450-469, 1986
26. Filler G, Lepage N, Delisle B, Mai I: Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther Drug Monit 23:514-519, 2001
27. Zucker K, Rosen A, Tsaroucha A, et al: Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol 5:225-232, 1997
28. Hubner G, Eismann R, Sziegoleit W: Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 21:536-539, 1999
29. Van Besouw NM, Van Der Mast BJ, Smak Gregoor PJ, et al: Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels. Nephrol Dial Transplant 14:2710-2713, 1999
30. Ojo AO, Meier-Kriesche HU, Hanson JA, et al: Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69:2405-2409, 2000
31. Kasiske BL, Chakkera HA, Louis TA, Ma JZ: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11:1910-1917, 2000